Glenmark Expands Ophthalmic Portfolio with Launch of Latanoprost Solution

Unknown Apr 02, 2026 2 Views

Glenmark Pharmaceuticals Inc., USA has announced the launch of Latanoprost Ophthalmic Solution, 0.005%, expanding its prescription ophthalmic product line. This generic version of Xalatan is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypert...

Stay Ahead – Explore Now! RBI Tightens Digital Lending Norms: LSPS Must Publish DLG Portfolio Details